Journal
AMERICAN JOURNAL OF TRANSPLANTATION
Volume 23, Issue 10, Pages 1603-1611Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajt.2023.05.032
Keywords
CD2/CD58; CD28/B7; siplizumab; belatacept; abatacept; mixed lymphocyte reaction
Categories
Ask authors/readers for more resources
Combined therapy of siplizumab with abatacept or belatacept can effectively suppress T cell proliferation, enhance siplizumab-mediated T cell inhibition, and improve the selective depletion of memory T cells. This combination therapy may be used for the prophylaxis of organ transplant rejection and improvement of long-term outcomes following transplantation.
Combined antigen-specific T cell receptor stimulation and costimulation are needed for complete T cell activation. Belatacept and abatacept are nondepleting fusion proteins blocking CD28/B7 costimulation, whereas siplizumab is a depleting antiCD2 immunoglobulin G1 monoclonal antibody targeting CD2/CD58 costimulation. Herein, the effect of siplizumab combination therapy with abatacept or belatacept on T cell alloreactivity in mixed lymphocyte reactions was investigated. In contrast to monotherapy, the combination of siplizumab with belatacept or abatacept induced near-complete suppression of T cell proliferation and increased the potency of siplizumab-mediated T cell inhibition. Furthermore, dual targeting of CD2 and CD28 costimulation enhanced the selective depletion of memory T cells compared with monotherapy. Although siplizumab monotherapy leads to significant regulatory T cell enrichment, high doses of cytotoxic T-lymphocyte-associated antigen 4 and a human IgG1 Fc fragment in the combination therapy reduced this effect. These results support the clinical evaluation of dual costimulation blockade, combining siplizumab with abatacept or belatacept, for the prophylaxis of organ transplant rejection and improvement of long-term outcomes following transplantation. Ongoing investigative research will elucidate when other forms of siplizumab-based dual costimulatory blockade may be able to induce similarly strong inhibition of T cell activation although still allowing for enrichment of regulatory T cells.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available